Collagen copolymer toric posterior chamber phakic intraocular lens for myopic astigmatism: One-year follow-up

Abstract

To assess the predictability, efficacy, safety, and stability of collagen copolymer toric phakic intraocular lens (pIOL) implantation to correct moderate to high myopic astigmatism. Fernández-Vega Ophthalmological Institute, Oviedo, Spain. This study comprised eyes that had implantation of a toric Intraocular Collamer Lens for moderate to high myopic astigmatism. The uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, pIOL vault, and adverse events were evaluated over 12 months. Preoperatively, the mean sphere in the 55 eyes was -4.65 diopters (D) +/- 3.02 (SD) (range -0.50 to -12.50 D) and the mean cylinder, -3.03 +/- 0.79 D (range -1.25 to -4.00 D). At 12 months, the mean Snellen decimal UDVA was 0.80 +/- 0.20 and the mean CDVA, 0.85 +/- 0.18; 62.0% of eyes had a CDVA of 20/20. More than 50.0% of eyes gained 1 or more lines of CDVA. The treatment was highly predictable for spherical equivalent (SE) (r(2) = 0.99) and astigmatic components J0 (r(2) = 0.97) and J45 (r(2) = 0.99). Of the eyes, 94.5% were within +/-0.50 D of the attempted SE and all were within +/-1.00 D. For J0, 94.5% of eyes were within +/-0.50 D and for J45, 98.2% of eyes; all eyes were within +/-1.00 D. The efficacy index was 0.95 at 3 months and 1.08 at 1 year. The UDVA and CDVA with toric pIOLs were good and highly stable over 12 months, confirming the procedure is safe, predictable, and effective for correction of moderate to high astigmatic.